Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Ricker E, Verma A, Marullo R, Gupta S, Ye C, Pannellini T, et al. Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma. Sci Rep. 2020;10(1):13094.

Gray KD, McCloskey JE, Vedvyas Y, Kalloo OR, Eshaky SE, Yang Y, et al. PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer. Clin Cancer Res. 2020;26(22):6003-6016.

Hashim D, Gonzalez-Feliciano AG, Ahearn TU, Pettersson A, Barber L, Pernar CH, et al. Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer. Int J Cancer. 2020;146(10):2694-2702.

Saqi A, Mukhopadhyay S, Butt Y, Doxtader E, Heymann JJ, Larsen BT, et al. E-cigarette or vaping product use-associated lung injury: What is the role of cytologic assessment? Cancer Cytopathol. 2020;128(6):371-380.

Gomez-Arteaga A, Orfali N, Guarneri D, Cushing MM, Gergis U, Hsu JM, et al. Cord blood transplants supported by unrelated donor CD34 progenitor cells. Bone Marrow Transplant. 2020;55(12):2298-2307.

Zanettini C, Omar M, Dinalankara W, Imada EL, Colantuoni E, Parmigiani G, et al. Influenza Vaccination and COVID19 Mortality in the USA. medRxiv. 2020.

Fajgenbaum DC, Wu D, Goodman A, Wong R, Chadburn A, Nasta S, et al. Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. Am J Hematol. 2020;95(12):1553-1561.

Chiang GC, Pisapia DJ, Liechty B, Magge R, Ramakrishna R, Knisely J, et al. The Prognostic Value of MRI Subventricular Zone Involvement and Tumor Genetics in Lower Grade Gliomas. J Neuroimaging. 2020;30(6):901-909.

Laurence J, J Mulvey J, Seshadri M, Racanelli A, Harp J, Schenck EJ, et al. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Clin Immunol. 2020;219:108555.

Manur R, Sung PJ, Loren AW, Ritchie EK, Frank D, Bagg A, et al. Leukemic lineage switch in a t(8;22)(p11.2;q11.2)/-rearranged myeloid/lymphoid neoplasm with mutation - diagnostic pitfalls and clinical management including FGFR1 inhibitor pemigatinib. Leuk Lymphoma. 2020;61(2):450-454.